Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo

Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $20 from $29 and keeps an Equal Weight rating on the shares. While the move on Monday may be “a tad overdone,” the firm thinks shares reflect more appropriate out year revs for elegrobart given its profile. In the near term, the setup for shares could be challenging, and Wells remains on the sidelines.